Actinium Pharmaceuticals (ATNM)
(Real Time Quote from BATS)
$7.96 USD
+0.22 (2.84%)
Updated Jul 25, 2024 10:44 AM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
ATNM 7.96 +0.22(2.84%)
Will ATNM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ATNM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ATNM
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
Is Affimed (AFMD) Outperforming Other Medical Stocks This Year?
ATNM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
Finch Therapeutics Group, Inc. (FNCH) Reports Q3 Loss, Misses Revenue Estimates
Actinium (ATNM) Stock Jumps 8.6%: Will It Continue to Soar?
Other News for ATNM
Actinium Pharmaceuticals' IND application in sickle cell disease approved by FDA
Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University
Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US
Buy Rating Reiterated for Actinium Pharmaceuticals Amid Promising AML Therapy Developments
Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Syndax Pharmaceuticals (SNDX)